Once-Weekly Mazdutide Shows Significant Weight Loss in Obesity and Overweight

The global obesity epidemic continues to pose a major public health challenge, contributing to numerous comorbidities like type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). While existing pharmacological interventions, including GLP-1 receptor agonists, have shown efficacy, there remains a critical need for novel, highly effective, and well-tolerated treatments to achieve substantial and sustained weight loss. This study addresses the knowledge gap regarding the efficacy and safety profile of Mazdutide, a novel dual GLP-1 and GIP receptor agonist, for weight management in adults.

The study demonstrated a dose-dependent and statistically significant reduction in body weight with Mazdutide compared to placebo. Participants receiving 9 mg Mazdutide achieved a mean body weight reduction of 15.1% from baseline, significantly greater than the 2.3% reduction observed in the placebo group (p<0.001). The 6 mg dose resulted in a 12.8% weight reduction, and the 3 mg dose showed a 9.5% reduction. The 9 mg dose of Mazdutide led to a mean body weight reduction of 15.1% from baseline, significantly outperforming placebo's 2.3% reduction over 24 weeks, establishing its potent anti-obesity effect. A remarkable 75% of participants in the 9 mg Mazdutide group achieved ≥10% body weight loss, compared to only 15% in the placebo group (p<0.001). Furthermore, 43% of individuals on 9 mg Mazdutide achieved ≥15% weight loss, a threshold often associated with significant health benefits. Improvements were also noted in key cardiometabolic markers, including a 25% reduction in fasting glucose and an 18% reduction in triglycerides in the highest dose group, alongside a 1.2% decrease in HbA1c (a measure of long-term blood sugar control) for those with prediabetes. The most common adverse events were mild-to-moderate gastrointestinal issues (nausea, diarrhea, vomiting), consistent with incretin-based therapies, with a 5% discontinuation rate due to adverse events in the 9 mg group.